KLOW Peptide Dosing & Reconstitution Calculator and Protocol Guide

What’s in a KLOW Vial

A standard 80 mg KLOW vial contains 50 mg GHK-Cu and 10 mg each of BPC-157, TB-4, and KPV. The most common protocol doses KLOW with 2 mg of GHK-Cu as the anchor, with 400 mcg each of BPC-157, TB-4, and KPV per injection. For non-standard vials, the KLOW Calculator calculates dosing for any vial mix and desired dose.

The four peptides in KLOW

GHK-Cu. Builds new collagen and clears damaged tissue at the same time (copper-peptide signaling, lysyl oxidase cross-linking¹). Most collagen interventions only do the second; this is what makes KLOW a skincare stack.

BPC-157. Sprouts new small blood vessels into the dermal repair area (angiogenic signaling²). Without that capillary supply, GHK-Cu has the signal but no nutrient delivery to the treatment site.

TB-4 (full-length thymosin β4, 43 aa) — Moves repair cells (fibroblasts) into position and biases healing toward functional tissue rather than rope-like scarring (G-actin sequestration³, Ac-SDKP anti-fibrotic fragment⁴).

KPV. Pre-empts the inflammation switch before it activates, so reactive skin doesn’t drown the rebuilding signals (NF-κB inhibition⁵). Normal immune signaling stays intact.

KPV is the anti-inflammatory component that distinguishes KLOW from GLOW. With GHK-Cu as the anchor, TB-4 lands at 400 mcg per injection. This supports background tissue organization but is below the bolus used in injury protocols. The injury protocol addresses that limitation separately.

KLOW is not FDA approved, and no controlled trial has evaluated the blend. The protocol is derived from component-level research and practitioner use; combination efficacy and long-term safety remain unmeasured. BPC-157's 2026 compounding-status changes affect access but do not establish efficacy or safety.

For component-level mechanisms, see the guides to BPC-157, TB-500 / TB-4, GHK-Cu, and KPV.

KLOW Dosing Protocols: Skincare vs. Injury Healing

Skincare: Anchored to GHK-Cu, which drives collagen rebuilding. KPV keeps reactive inflammation off, BPC-157 and TB-4 hold up blood-flow and repair-cell traffic in the background.

Injury healing: Anchored to BPC-157, which drives tissue repair alongside TB-4; KPV pre-empts the inflammatory signals that bottleneck healing; GHK-Cu strengthens the connective-tissue framework as the repair lays down.

Both anchors land on a clean 10-unit daily draw on a U-100 insulin syringe. Use the KLOW Dosage Calculator above to solve any custom anchor dose or vial size.

KLOW protocol for skincare

The skincare protocol is anchored on 2 mg GHK-Cu per injection, daily and subcutaneous, which delivers 400 mcg each of BPC-157, TB-4, and KPV per injection.

At this dose, an 80 mg vial contains 25 doses — well inside the 28-day refrigerated stability window.

A standard cycle runs 12 weeks across three phases, followed by 4–8 weeks off. Continuous daily use is not the default.

Expect visible texture and tone improvement by week 3–4, fine lines softening by 4–6, structural firmness and scar remodeling by 8–12. Phasing and lifestyle inputs are covered in Supporting Factors below.

KLOW protocol for injury

BPC-157 is the injury anchor in this blend². The protocol uses 0.5 mg (500 mcg) per injection, daily and subcutaneous, with near-injury placement when practical. A vial supplies 20 daily doses at the 2 mL reconstitution.

TB-4's concentration-dependent mechanism favors a bolus rather than a small daily dose³. At 0.5 mg per draw, BPC-157 and KPV are within the protocol range, but TB-4 is not. Raising the KLOW dose to compensate would also raise GHK-Cu excessively.

Practitioner protocols address this with a separate full-length TB-4 bolus of 2–4 mg, two or three times weekly, alongside daily KLOW. Frequency typically falls from three doses per week in weeks 1–4 to two in weeks 5–8.

TB-500 (the 17–23 fragment) is an acceptable substitute when full-length isn’t available, but labels blur the two routinely⁸ — verify what’s in the vial. The Ac-SDKP anti-fibrotic action⁴ that produces functional rather than rope-like tissue runs through full-length, not the fragment.

Neither TB-4 nor BPC-157 "stays local" — both enter systemic circulation within minutes — but first-pass tissue concentration is higher at the injection site before systemic dilution⁷, which matters disproportionately for TB-4's concentration-dependent mechanism. See where to inject KLOW peptide for the full anatomical breakdown.

Standard cycle: 8–12 weeks active, then 4–8 weeks off, with the same three-phase frequency taper. Expect inflammation reduction by week 2, functional improvement by week 4–6, structural progress through week 12.

For the broader injury-recovery framework (five-compound protocol, NAD+ metabolic support), see the Injury Recovery Peptide Protocol; for the simpler two-compound baseline, see the BPC-157 + TB-500 Wolverine Stack.

Why the standard KLOW ratios fall short for serious injury

At the injury anchor, three of the four peptides land usefully, but the cocktail is a base, not a complete injury protocol. The fixed ratios were built for skin’s continuous collagen demand, not soft tissue’s coupled bottlenecks.

The two real gaps are TB-4 saturation, closed by the bolus above, and NAD+, which the cocktail cannot carry because it is acidic and degrades peptides on contact. For a complete soft-tissue protocol, run the compounds individually: the Wolverine Stack (BPC-157 + TB-500) for simple repair, or the Injury Recovery Protocol for the five-compound version with NAD+.

How KLOW Works

Skin aging and skin inflammation are several systems failing at once: collagen genes firing less, the capillary supply thinning, repair cells losing coordination, and inflammatory tone interfering with all of it. KLOW assigns one peptide to each bottleneck. KPV is the piece GLOW lacks, so it leads here.

KPV: inflammation control

KPV is a three-amino-acid fragment of alpha-MSH, a natural anti-inflammatory hormone. It stops inflammatory genes from switching on in the first place (NF-κB inhibition⁵), a different approach from NSAIDs that block inflammation after it has already started, and normal immune signaling needed for healing stays intact.

On reactive skin, redness and flushing settle before the slower collagen work surfaces — most users notice baseline redness drop in the first one to two weeks.

KPV’s strongest preclinical evidence is for oral delivery to gut tissue, where inflamed cells actively absorb it⁶. Subcutaneous KLOW distributes it systemically instead, which suits skin-local inflammation but has not been tested in controlled human trials for blends like this.

GHK-Cu: collagen and structure

GHK-Cu is a copper-binding tripeptide mapped across more than 4,000 genes — collagen synthesis, antioxidant defense, and wound-healing programs trend up, while inflammation and tissue-breakdown programs trend down¹. Circulating levels fall with age, from roughly 200 ng/mL at 20 to about 80 ng/mL by 60¹.

It clears damaged matrix as well as laying down new collagen, where most collagen interventions only do the second. The copper it carries is also what turns the solution blue and produces the brief sting on injection.

BPC-157: blood supply

BPC-157 is a 15-amino-acid fragment from gastric juice. It builds the capillary network active regeneration depends on (new blood vessel formation²) and stabilizes tissue barriers so new tissue holds together. Without blood flow to the dermis, GHK-Cu has the signal but the raw material never reaches the work.

TB-4: cell migration

Full-length thymosin beta-4 (43 amino acids) governs how repair cells move into tissue and organize once they arrive (G-actin sequestration³). It biases healing toward functional tissue over rope-like scarring (Ac-SDKP anti-fibrotic signaling⁴) and helps inflammation resolve cleanly. KLOW uses the full-length parent, not the shorter TB-500 fragment sold for injury work; the two are blurred on labels routinely⁸, so confirm what sequence is in the vial.

KLOW Protocol Add-Ons: Conditional Peptide Stacks

NAD+ is the primary metabolic add-on considered for KLOW. It may be relevant when remodeling occurs under metabolic strain, including GLP-1 use, caloric deficit, chronic fatigue, or age-related NAD+ decline. Practitioner protocols use 100–200 mg IM, two or three times weekly. NAD+ requires a different syringe and site because its acidity can degrade peptides on contact.

KLOW alone handles the standard reactive-skin / inflammation-driven baseline. The remaining layers are conditional — added only when a specific bottleneck shows up, not by default:

Selank. Fits when stress-triggered flushing rides alongside reactive skin. Closes the cortisol and nervous-system pathway that keeps the flushing going (HPA-axis pattern). Particularly relevant for stress-driven rosacea.

SS-31. Fits active procedure recovery (laser, microneedling, peels) with high oxidative stress or slow rebound. Supports the energy-producing structures inside cells during the high-stress repair window (mitochondrial-membrane stabilization). KLOW begins roughly 48–72 hours post-procedure once the initial inflammation has peaked.

Sermorelin / Tesamorelin / Ipamorelin. Only for the growth-hormone-deficiency pattern (poor sleep + low recovery). Not a default layer.

Build a stack with FoxAI→

Phenotype Considerations

Perimenopausal users. Estrogen-driven collagen decline accelerates during perimenopause, and substrate is typically already more depleted at baseline. The fit is a 12-week activation phase rather than 8.

Recent surgery. The convention defers at least two weeks after major surgery. Excessive angiogenesis during early surgical healing can complicate scar formation.

Post-procedure (laser, microneedling, peels). KLOW can begin roughly 48–72 hours after minor procedures, once the initial inflammatory cascade has peaked, with any new compounds held through the acute first week.

Persistent inflammation past week 6 on KLOW. The driver may be systemic or involve a different pathway, including mast-cell activation. This pattern warrants reassessment rather than automatic dose escalation.

Supporting Factors

These inputs support tissue synthesis, collagen cross-linking, matrix hydration, copper balance, and overnight repair.

When Progress Stalls

The stall pattern is the thing to read, rather than pushing the dose harder.

Plateau at week 4–6 with clean execution. The architectural work has hit its energy envelope. NAD+ or tightened recovery support is what addresses it; escalating KLOW does not.

Inflammation persists past week 6. The driver may be mast-cell-mediated or systemic rather than NF-κB-local, so dose escalation will not reach it — see the mast-cell note under Phenotype Considerations.

Weak results across the board. Usually substrate shortage. The protein floor, vitamin C, copper-zinc balance, reconstitution and storage technique, and sleep are the checks before adding compounds.

Skin calms but gut symptoms remain. Subcutaneous KLOW does not reach the gut surface; KPV’s gut work runs through the oral PepT1 route⁶. The gut is a separate route and problem.

Safety & Considerations

Active malignancy or cancer history within the past five years. GHK-Cu, BPC-157, and TB-4 all promote new blood-vessel formation — a hard contraindication during active cancer treatment, and a caution within five years of remission given the theoretical risk of supporting tumor blood supply.

Wilson’s disease or copper overload. GHK-Cu delivers 50 mg copper-bound peptide per vial; contraindicated in anyone with copper-handling disorders.

Pregnancy or breastfeeding. No safety data for any of the four peptides during pregnancy.

WADA-tested athletes. TB-4 is on the prohibited list; KLOW is not usable in-competition.

Baseline photos if skincare is the goal. Progress on skin is gradual; week-0 photos are the only reliable progress marker at week 6.

Conventional approaches to reactive skin include topical metronidazole, azelaic acid, oral antibiotics, and post-procedure corticosteroids. These options have different evidence bases, mechanisms, and adverse-effect profiles from KLOW.

What Evidence Exists

GHK-Cu. Split-face human dermatology trials on wrinkle depth and skin density (n usually under 50 per arm); microarray gene mapping (4,000+ genes); decades of cosmetic and wound-healing literature. No multi-center RCT.

BPC-157. 100+ preclinical repair studies; human evidence is thin but real — PL-14736 (its clinical-development name) reached abstract-level Phase 1/2 in ulcerative colitis, a modern hamstring tendon Phase 2 RCT is recruiting, and an intra-articular knee case series exists. Clean early-phase safety; no completed modern RCT.

TB-4. Substantial human trial data for full-length TB-4 (corneal-healing Phase 2/3 as RGN-259, plus cardiac and wound-repair programs), with clean Phase 1 safety⁹; cosmetic dosing extrapolated from these. Full-length trial data does not transfer to the TB-500 fragment, so verify vial identity.

KPV. Mechanistic NF-κB data; small clinical trials in IBD (oral) and atopic dermatitis (topical/oral). No published subcutaneous human data for systemic effects.

No controlled trial has evaluated KLOW as a blend. Synergy is inferred from the individual mechanisms, not demonstrated in combination.

How KLOW Dosage and Reconstitution Are Calculated

KLOW is a fixed-ratio blend, so the correct starting point is the peptide that owns the goal. Use GHK-Cu as the anchor for skincare and BPC-157 as the anchor for injury support; the other three peptides scale automatically because every draw preserves the vial’s 50/10/10/10 ratio.

The two standard setups both land on 0.1 mL, or 10 units on a U-100 syringe. A 2 mg GHK-Cu skincare anchor uses 2.5 mL of BAC water and delivers 0.4 mg each of BPC-157, TB-4, and KPV. A 0.5 mg BPC-157 injury anchor uses 2 mL of BAC water and delivers 2.5 mg GHK-Cu plus 0.5 mg each of TB-4 and KPV.

For any custom anchor, calculate the draw with:

Draw volume in mL = anchor dose × BAC water volume ÷ anchor mass in the vial.

The anchor mass is 50 mg for GHK-Cu or 10 mg for BPC-157. BAC water changes concentration and syringe volume; it does not change the vial ratio or the amount delivered by a correctly calculated draw.

To reconstitute, wipe both stoppers, let the BAC water run down the inside vial wall, and swirl gently without shaking. The dissolved solution should be clear blue from GHK-Cu. The KLOW Calculator handles custom anchors; the FAQ below gives alternate dilution and injection details.

FAQ

Related Topics

• KLOW Dosing Calculator — Reconstitution and per-dose math for any anchor dose or vial size
• Peptide Calculator — General-purpose reconstitution and dosing calculator
• Injury Recovery Peptide Protocol — Five-compound structural repair framework including NAD+ metabolic support
• BPC-157 + TB-500 Wolverine Stack — Simpler injury recovery stack centered on the two core repair peptides
• BPC-157 Guide — Standalone dosing, pharmacokinetics, oral vs injectable
• TB-500 / TB-4 Guide — Fragment vs full-length, CoA verification, threshold-saturation mechanism
• GHK-Cu Guide — Copper peptide mechanism for skin and matrix quality
• KPV Guide — Anti-inflammatory mechanism, gut and skin applications
• NAD+ Guide — Cellular energy support for intensive repair cycles
• Peptide Reconstitution Guide — General bacteriostatic water and syringe handling
• Where to Inject KLOW Peptide — Near-injury vs systemic injection routing

References

¹ GHK-Cu tissue-organization signaling and copper-peptide complex — TGF-β/Smad matrix organization, lysyl oxidase cross-linking, SOD/catalase antioxidant expression, copper coordination chemistry, 4,000+ gene modulation: PubMed 29986520; age-related plasma decline (roughly 200 ng/mL at age 20 to about 80 ng/mL by 60): Pickart L, Margolina A. Int J Mol Sci 2018. PMC6073405

² BPC-157 angiogenic signaling — VEGFR2–Akt–eNOS activation, nitric oxide bioavailability, FAK-paxillin cell-anchoring cascade, anti-cytokine modulation: PMC8275860

³ TB-4 / TB-500 G-actin sequestration and threshold-saturation mechanism — actin-monomer binding, cytoskeletal mobilization for cell migration, mass-action pharmacodynamics requiring bolus dosing: PubMed 12581423

⁴ TB-4 Ac-SDKP anti-fibrotic fragment — N-terminal tetrapeptide (fragment 1–4) released by meprin-α and POP processing; suppresses TGF-β-driven fibrosis and cardiac/renal remodeling: PMC4889319; fragment-specific activity review: PMC8724243

⁵ KPV NF-κB inhibition — blocks nuclear translocation of NF-κB, suppresses TNF-α/IL-6/IL-8/IL-1β transcription, preserves normal immune signaling: PubMed 18061177

⁶ KPV PepT1-mediated uptake in inflamed tissue — Dalmasso G et al. "PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation." Gastroenterology. 2008;134:166-178. PubMed 18068698

⁷ TB-4 local-vs-systemic tissue concentration — biodistribution data showing systemic dilution after subQ/IM injection; local injection produces higher first-pass tissue concentration; free systemic TB-4 at matched total doses produced zero cardiac functional improvement vs locally-targeted nanoparticle formulations: PubMed 12581423

⁸ TB-4 / TB-500 product mislabeling — documented bidirectional mislabeling between full-length TB-4 (43 aa) and the TB-500 fragment (residues 17–23) in marketed peptide products: Esposito M et al. Drug Test Anal 2012. PubMed 22962027

⁹ TB-4 Phase 1 human safety — first-in-human randomized, double-blind, single- and multiple-dose Phase 1 of recombinant human thymosin β4 in healthy volunteers, no serious adverse events: PubMed 34346165; intravenous TB-4 Phase 1 safety and pharmacokinetics, no dose-limiting or serious adverse events (Ann N Y Acad Sci 2010;1194:223–229): NCT00743769